Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2022 | 1133 | 1.530 |
Why?
|
| Biomarkers, Tumor | 8 | 2022 | 466 | 1.390 |
Why?
|
| Glypicans | 3 | 2009 | 6 | 0.950 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 860 | 0.760 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 168 | 0.700 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 278 | 0.650 |
Why?
|
| Keratins | 1 | 2016 | 31 | 0.540 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2014 | 47 | 0.530 |
Why?
|
| Curettage | 2 | 2020 | 8 | 0.520 |
Why?
|
| Antibodies | 1 | 2016 | 180 | 0.510 |
Why?
|
| Uterine Diseases | 1 | 2014 | 9 | 0.470 |
Why?
|
| Endometrium | 1 | 2014 | 29 | 0.460 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2014 | 2 | 0.450 |
Why?
|
| Specimen Handling | 1 | 2014 | 60 | 0.450 |
Why?
|
| Biopsy | 1 | 2014 | 410 | 0.410 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 45 | 0.380 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 72 | 0.280 |
Why?
|
| Female | 18 | 2022 | 31733 | 0.270 |
Why?
|
| Melanoma | 1 | 2009 | 337 | 0.250 |
Why?
|
| Urinary Bladder Diseases | 1 | 2004 | 8 | 0.240 |
Why?
|
| Mullerian Ducts | 1 | 2004 | 4 | 0.240 |
Why?
|
| Urinary Bladder | 1 | 2004 | 37 | 0.230 |
Why?
|
| Humans | 22 | 2022 | 60999 | 0.210 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2022 | 63 | 0.200 |
Why?
|
| Mammography | 2 | 2022 | 273 | 0.200 |
Why?
|
| Microscopy | 1 | 2022 | 88 | 0.190 |
Why?
|
| Colposcopy | 1 | 2020 | 22 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 5288 | 0.180 |
Why?
|
| Cervix Uteri | 1 | 2020 | 57 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2022 | 143 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 332 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 147 | 0.160 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 10 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 24 | 0.150 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 58 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2022 | 623 | 0.120 |
Why?
|
| Middle Aged | 7 | 2020 | 16872 | 0.120 |
Why?
|
| Cytodiagnosis | 2 | 2022 | 44 | 0.120 |
Why?
|
| Aged | 6 | 2018 | 13876 | 0.120 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2014 | 3 | 0.110 |
Why?
|
| Observer Variation | 1 | 2014 | 212 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2014 | 40 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2012 | 54 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2012 | 47 | 0.100 |
Why?
|
| Prognosis | 2 | 2014 | 1631 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2012 | 23 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 33 | 0.100 |
Why?
|
| Tonsillar Neoplasms | 1 | 2011 | 1 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1128 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 118 | 0.090 |
Why?
|
| Mesothelioma, Cystic | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 29 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2011 | 60 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 216 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
|
| Adult | 5 | 2020 | 16226 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 721 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1549 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 208 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 499 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 240 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 32 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 328 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2012 | 944 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 138 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 108 | 0.070 |
Why?
|
| Male | 4 | 2011 | 28463 | 0.060 |
Why?
|
| Radar | 1 | 2022 | 4 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 592 | 0.050 |
Why?
|
| Wireless Technology | 1 | 2022 | 18 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2022 | 23 | 0.050 |
Why?
|
| Breast | 1 | 2022 | 173 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 140 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 163 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 276 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 248 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2018 | 219 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 178 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 462 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2012 | 34 | 0.030 |
Why?
|
| Optics and Photonics | 1 | 2012 | 13 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 2012 | 32 | 0.020 |
Why?
|
| Methylene Blue | 1 | 2012 | 23 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 222 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 399 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 310 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 228 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 378 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 285 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 416 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 652 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 217 | 0.020 |
Why?
|
| Asthma | 1 | 2011 | 463 | 0.020 |
Why?
|
| Hypertension | 1 | 2011 | 616 | 0.020 |
Why?
|
| Neoplasms | 1 | 2012 | 1269 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6201 | 0.010 |
Why?
|